About Collegium Pharmaceutical, Inc.
https://www.collegiumpharma.comCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
CEO
Vikram Karnani
Compensation Summary
(Year 2024)
Salary $364,423
Stock Awards $9,372,916
All Other Compensation $952,513
Total Compensation $10,689,852
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public May 7, 2015
Method of going public IPO
Full time employees 357
ETFs Holding This Stock
Summary
Total 180
Showing Top 3 of 180
Ratings Snapshot
Rating : B
Discounted Cash Flow 3
Return On Equity 5
Return On Assets 3
Debt To Equity 1
Price To Earnings 2
Price To Book 2
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 3
Neutral 1
Showing Top 4 of 4
Price Target
Target High $58
Target Low $55
Target Median $56.5
Target Consensus $56.5
Institutional Ownership
BLACKROCK INC.
Shares:5.79M
Value:$269.8M
BLACKROCK, INC.
Shares:5.18M
Value:$241.14M
RUBRIC CAPITAL MANAGEMENT LP
Shares:2.83M
Value:$131.63M
Summary
% Of Shares Owned 104.09%
Total Number Of Holders 287
Showing Top 3 of 287
Market Cap $1.54 B
52w High $50.79
52w Low $23.23
P/E 28.57
Volume 539.27K
Outstanding Shares 31.61M
About Collegium Pharmaceutical, Inc.
https://www.collegiumpharma.comCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $209.36M ▲ | $65.55M ▼ | $31.51M ▲ | 15.05% ▲ | $1 ▲ | $121.71M ▲ |
| Q2-2025 | $188M ▲ | $73.28M ▼ | $11.98M ▲ | 6.37% ▲ | $0.38 ▲ | $94.1M ▲ |
| Q1-2025 | $177.76M ▼ | $75.64M ▲ | $2.42M ▼ | 1.36% ▼ | $0.08 ▼ | $80.48M ▼ |
| Q4-2024 | $181.95M ▲ | $60.18M ▼ | $12.54M ▲ | 6.89% ▲ | $0.39 ▲ | $96.44M ▲ |
| Q3-2024 | $159.3M | $61.95M | $9.34M | 5.86% | $0.33 | $75.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $305.71M ▲ | $1.61B ▲ | $1.33B ▼ | $274.81M ▲ |
| Q2-2025 | $222.15M ▲ | $1.59B ▼ | $1.36B ▼ | $232.21M ▼ |
| Q1-2025 | $197.77M ▲ | $1.63B ▼ | $1.4B ▼ | $234.43M ▲ |
| Q4-2024 | $162.76M ▲ | $1.66B ▲ | $1.43B ▲ | $228.84M ▼ |
| Q3-2024 | $119.96M | $1.64B | $1.4B | $234.28M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $31.51M ▲ | $78.44M ▲ | $-30.87M ▼ | $-14.82M ▲ | $32.75M ▲ | $78.25M ▲ |
| Q2-2025 | $11.98M ▲ | $72.44M ▲ | $-2.92M ▲ | $-48.37M ▼ | $21.15M ▲ | $72.37M ▲ |
| Q1-2025 | $2.42M ▼ | $55.4M ▼ | $-9.68M ▲ | $-25.24M ▲ | $20.48M ▼ | $54.6M ▼ |
| Q4-2024 | $12.54M ▲ | $84.64M ▲ | $-11.76M ▲ | $-41.28M ▼ | $31.61M ▲ | $84.07M ▲ |
| Q3-2024 | $9.34M | $-9M | $-248.96M | $149.03M | $-108.93M | $-9.24M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Belbuca | $110.00M ▲ | $50.00M ▼ | $50.00M ▲ | $60.00M ▲ |
 Nucynta ER | $40.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Nucynta IR | $50.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
 Symproic | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Xtampza ER | $100.00M ▲ | $50.00M ▼ | $50.00M ▲ | $50.00M ▲ |
CEO
Vikram Karnani
Compensation Summary
(Year 2024)
Salary $364,423
Stock Awards $9,372,916
All Other Compensation $952,513
Total Compensation $10,689,852
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Went public May 7, 2015
Method of going public IPO
Full time employees 357
ETFs Holding This Stock
Summary
Total 180
Showing Top 3 of 180
Ratings Snapshot
Rating : B
Discounted Cash Flow 3
Return On Equity 5
Return On Assets 3
Debt To Equity 1
Price To Earnings 2
Price To Book 2
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 3
Neutral 1
Showing Top 4 of 4
Price Target
Target High $58
Target Low $55
Target Median $56.5
Target Consensus $56.5
Institutional Ownership
BLACKROCK INC.
Shares:5.79M
Value:$269.8M
BLACKROCK, INC.
Shares:5.18M
Value:$241.14M
RUBRIC CAPITAL MANAGEMENT LP
Shares:2.83M
Value:$131.63M
Summary
% Of Shares Owned 104.09%
Total Number Of Holders 287
Showing Top 3 of 287